Patent intelligence · US
US 10233206
D-fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response
D-fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response
Patent details — US 10233206
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 19, 2019
- Expiration
- Mar 14, 2039
- Applicant
- SERGIO PUMAROLA SEGURA
- Claims
- 18
- CPC classes
- A61K, A61K31/445, A61K31/7008, A61K31/7048
Quick answer
US 10233206 (D-fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response) is held by SERGIO PUMAROLA SEGURA. Status: granted. Granted Mar 19, 2019. Expires Mar 14, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SERGIO PUMAROLA SEGURA
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/445, A61K31/7008, A61K31/7048, A61K36/48, A61K36/605
Frequently asked questions
What is US patent 10233206?
US 10233206 (D-fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response) is held by SERGIO PUMAROLA SEGURA. Status: granted. Granted Mar 19, 2019. Expires Mar 14, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10233206?
SERGIO PUMAROLA SEGURA is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 10233206 expire?
Our index shows an expiration date of Mar 14, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.